A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : TACE

Search Conditions:
Search Keyword : TACE
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: TACE
Appearance Frequency: 5185 time(s)
Long forms: 53

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
transarterial chemoembolization
(4503 times)
Neoplasms
(1324 times)
HCC (3026 times)
OS (781 times)
RFA (418 times)
1985 [A newly devised chemo-embolic agent, G. T. XIII-ADM].
TNF-alpha converting enzyme
(325 times)
Biochemistry
(48 times)
TNF-alpha (71 times)
TNF (50 times)
EGFR (20 times)
1997 Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.
tumor necrosis factor-alpha converting enzyme
(254 times)
Biochemistry
(76 times)
PMA (29 times)
EGFR (21 times)
ERK (19 times)
1998 2 angstrom X-ray structure of adamalysin II complexed with a peptide phosphonate inhibitor adopting a retro-binding mode.
TACE group
(17 times)
Neoplasms
(5 times)
HCC (14 times)
RFA (7 times)
OS (4 times)
2003 Expression of angiogenic factors in hepatocellular carcinoma after transcatheter arterial chemoembolization.
TNF-alpha convertase
(14 times)
Biochemistry
(3 times)
TNF-alpha (9 times)
iNOS (3 times)
ADAM (2 times)
1999 Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.
tumour necrosis factor alpha convertase
(12 times)
Biochemistry
(5 times)
ACE2 (1 time)
Ang II (1 time)
autoAbs (1 time)
1999 Evidence for an interaction of the metalloprotease-disintegrin tumour necrosis factor alpha convertase (TACE) with mitotic arrest deficient 2 (MAD2), and of the metalloprotease-disintegrin MDC9 with a novel MAD2-related protein, MAD2beta.
Tolerance, Annoyed, Cut down, Eye-opener
(6 times)
Obstetrics
(2 times)
AUDIT (3 times)
AUDIT-C (1 time)
AUROC (1 time)
2006 Estimates of prenatal abstinence from alcohol: a matter of perspective.
Tri-panisyl chloroethylene
(4 times)
Obstetrics
(2 times)
--- 1952 Estrogenic effect of tri-p-anisylchloroethylene (TACE) in the human postmenopausal female.
transarterial chemotherapy
(3 times)
Medicine
(1 time)
HCC (2 times)
PPI (1 time)
SIRT (1 time)
2018 [Hepatocellular Carcinoma: New multimodal therapy concepts].
10  TNF cleavage enzyme
(2 times)
Genetics, Medical
(1 time)
SNPs (1 time)
2010 Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response.
11  Transcatheter arterial chemoembolization with lipiodol
(2 times)
Gastroenterology
(2 times)
HCC (1 time)
RHCC (1 time)
1993 Chemoembolotherapy for recurrent hepatocellular carcinoma in the residual liver after hepatectomy.
12  tumor necrosis factor alpha-converting enzyme expression
(2 times)
Hematology
(1 time)
CLL (1 time)
M-CSF (1 time)
NF-kappaB (1 time)
2013 Breast tumor cell TACE-shed MCSF promotes pro-angiogenic macrophages through NF-kappaB signaling.
13  activity to alpha-secretase
(1 time)
Biology
(1 time)
--- 2012 beta-Secretase (BACE1) inhibitory property of loganin isolated from Corni fructus.
14  either a chemotherapy
(1 time)
Neoplasms
(1 time)
MWA (1 time)
PEI (1 time)
PVE (1 time)
2017 Other non-surgical treatments for liver cancer.
15  Furin-TNF-alpha-converting enzyme
(1 time)
Clinical Laboratory Techniques
(1 time)
Abs (1 time)
SGECs (1 time)
2010 RETRACTED: Blockade of TNF-alpha signaling suppresses the AREG-mediated IL-6 and IL-8 cytokines secretion induced by anti-Ro/SSA autoantibodies.
16  microspheres-transarterial chemoembolization
(1 time)
Gastroenterology
(1 time)
D-TACE (1 time)
2022 [Analysis of curative effects of chemoembolization with drug-loaded microspheres of different particle sizes for the treatment of hepatocellular carcinoma].
17  pembrolizumab-lenvatinib-transarterial chemoembolization
(1 time)
Neoplasms
(1 time)
AEs (1 time)
CI (1 time)
HR (1 time)
2021 Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
18  TACE alone
(1 time)
Medicine
(1 time)
HCC (1 time)
OS (1 time)
TACE-S (1 time)
2022 Transarterial chemoembolization with or without sorafenib for hepatocellular carcinoma: A real-world propensity score-matched study.
19  TACE without endostatin
(1 time)
Gastroenterology
(1 time)
HCC (1 time)
MVD (1 time)
TACE-V (1 time)
2012 Endostatin inhibits angiogenesis in hepatocellular carcinoma after transarterial chemoembolization.
20  TACE, labeled as TT
(1 time)
Liver Diseases
(1 time)
HCC (1 time)
2022 GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
21  TACE-BEV arm
(1 time)
Neoplasms
(1 time)
HCC (1 time)
OS (1 time)
PFS (1 time)
2012 Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study.
22  TACE-DEB is described
(1 time)
Radiology
(1 time)
--- 2013 Medico-economic study of the management of hepatocellular carcinoma by chemo-embolization.
23  TAPI-1, an inhibitor of another enzyme required for notch activity
(1 time)
Neurology
(1 time)
--- 2011 Inhibition of Notch activity promotes nonmitotic regeneration of hair cells in the adult mouse utricles.
24  Targeted Analysis of Chromatin Events
(1 time)
Molecular Biology
(1 time)
--- 2019 Targeted Analysis of Chromatin Events (TACE).
25  targeting of cell surface metalloprotease
(1 time)
Biological Phenomena
(1 time)
IBD (1 time)
2017 Increased Potency of a Bi-specific TL1A-ADAM17 (TACE) Inhibitor by Cell Surface Targeting.
26  Technology-assisted continuing education
(1 time)
Education, Nursing
(1 time)
--- 2019 Improving End-of-Life Communications Using Technology-Assisted Continuing Education With Interprofessional Teams.
27  time-to-complete response compared with that in Non-TT
(1 time)
Liver Diseases
(1 time)
HCC (1 time)
2022 GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
28  TNF-alpha ADAM metalloprotease converting enzyme
(1 time)
Cell Biology
(1 time)
AhR (1 time)
BSG (1 time)
IL-22 (1 time)
2017 Gene expression profiling of the Notch-AhR-IL22 axis at homeostasis and in response to tissue injury.
29  TNF-cleaving enzyme
(1 time)
Neurology
(1 time)
mTNFalpha (1 time)
SP (1 time)
sTNF-alpha (1 time)
2010 A novel cell-cell signaling by microglial transmembrane TNFalpha with implications for neuropathic pain.
30  trans-arterial therapies like chemoembolization
(1 time)
HCC (1 time)
2021 The Immunology of Hepatocellular Carcinoma.
31  transarterial chemoembolization chemoembolization
(1 time)
Radiology
(1 time)
CT (1 time)
HCC (1 time)
OS (1 time)
2012 CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement.
32  transarterial chemoembolization using lipiodol +/- gelatin sponge particles
(1 time)
Neoplasms
(1 time)
HCC (1 time)
PVTT (1 time)
2017 The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization.
33  transarterial chemoembolization with CPT-11 charged microbeads
(1 time)
Neoplasms
(1 time)
--- 2014 A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments.
34  transarterial platinum coil embolization
(1 time)
Brain
(1 time)
CCF (1 time)
TABE (1 time)
1997 [Transarterial platinum coil embolization for direct carotid-cavernous fistula].
35  transcatheter
(1 time)
Pharmacology
(1 time)
HCC (1 time)
MVD (1 time)
PI3K (1 time)
2016 Inhibition of human hepatocellular carcinoma tumor angiogenesis by siRNA silencing of VEGF via hepatic artery perfusion.
36  Transcatheter arterial chemoembolization LIHC, Liver hepatocellular carcinoma
(1 time)
Immune System Diseases
(1 time)
HCC (1 time)
ICIs (1 time)
TRD score (1 time)
2022 Development and Validation of TACE Refractoriness-Related Diagnostic and Prognostic Scores and Characterization of Tumor Microenvironment Infiltration in Hepatocellular Carcinoma.
37  transcatheter arterial chemoembolization using iodized oil mixed with anticancer drugs
(1 time)
Radiology
(1 time)
HCC (1 time)
RFA (1 time)
2005 [Low-output radiofrequency ablation combined with transcatheter arterial oily-chemoembolization for hepatocellular carcinoma].
38  transcatheter arterial chemoembolization/transarterial chemoembolization
(1 time)
Drug Therapy
(1 time)
HCC (1 time)
mAbs (1 time)
2017 Recent advances in hepatocellular carcinoma therapy.
39  transcatheter arterial chemotherapy
(1 time)
Gastroenterology
(1 time)
BCLC (1 time)
CNKI (1 time)
DFS (1 time)
2022 Efficacy and safety of preoperative transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
40  transcatheter arterial infusion chemotherapy
(1 time)
Radiology
(1 time)
ASC (1 time)
DSM (1 time)
2004 Case report: adenosquamous carcinoma of the liver successfully treated with repeated transcatheter arterial infusion chemotherapy (TACE) with degradable starch microspheres.
41  transhepatic arterial chemotherapeutic embolism
(1 time)
Neoplasms
(1 time)
HGF (1 time)
PLC (1 time)
2017 Effects of HGF gene polymorphisms and protein expression on transhepatic arterial chemotherapeutic embolism efficacy and prognosis in patients with primary liver cancer.
42  treated with chemoembolization
(1 time)
Gastroenterology
(1 time)
PVT (1 time)
2011 Chemoembolization for unresectable hepatocellular carcinoma in patients with or without portal vein thrombosis.
43  treatment for recurrence
(1 time)
General Surgery
(1 time)
HCC (1 time)
OS (1 time)
RTDS (1 time)
2014 Early intrahepatic recurrence of hepatocellular carcinoma after hepatectomy treated with re-hepatectomy, ablation or chemoembolization: a prospective cohort study.
44  Treatment of cancer of prostate & its metastases by chlorotrianisene
(1 time)
Urology
(1 time)
--- 1957 [Treatment of cancer of prostate & its metastases by chlorotrianisene (TACE)].
45  treatment of intermediate-stage HCC, i.e. BCLC's stage B, is chemoembolization
(1 time)
Neoplasms
(1 time)
BCLC (1 time)
HCC (1 time)
HIF-1 (1 time)
2012 Effective therapeutic management of hepatocellular carcinoma - on the basis of a clinical case.
46  treatment response after chemoembolisation
(1 time)
Hematology
(1 time)
CEUS (1 time)
CT (1 time)
HCC (1 time)
2014 Evaluation of treatment response after chemoembolisation (TACE) in hepatocellular carcinoma using real time image fusion of contrast-enhanced ultrasound (CEUS) and computed tomography (CT)--preliminary results.
47  treatment with chlorotrianisene
(1 time)
Urology
(1 time)
--- 1983 New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens.
48  treatments such as chemoembolization
(1 time)
Medicine
(1 time)
HCC (1 time)
2020 Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization.
49  trial of intraarterial hepatic chemoembolization
(1 time)
Neoplasms
(1 time)
--- 2008 Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study.
50  tumor model of hepatic arterial chemoembolization
(1 time)
Neoplasms
(1 time)
AUC (1 time)
GSMs (1 time)
2014 Pharmacokinetics of gelatin sponge microparticles in a rabbit VX2 liver tumor model of hepatic arterial chemoembolization.
51  tumor necrosis factor-alpha
(1 time)
Chemistry
(1 time)
MMP (1 time)
2004 Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitors.
52  tumors, chemoembolization
(1 time)
TAE (1 time)
TARE (1 time)
2016 Arterial Therapies of Non-Colorectal Liver Metastases.
53  Tumour Necrosis Factor-alpha Cleaving Enzyme
(1 time)
Pathology
(1 time)
MMP (1 time)
2000 Treatment with BB-94, a broad spectrum inhibitor of zinc-dependent metalloproteinases, causes deviation of the cytokine profile towards type-2 in experimental pulmonary tuberculosis in Balb/c mice.